Novavax will present encore safety and immunogenicity data from its COVID-19 vaccine (NVX-CoV2373) trials, as well as encore safety and efficacy data on the Novavax Influenza vaccine candidate at the Communicable Diseases & Immunisation Conference (CDIC) 2022 in Sydney, Australia, from June 20 to 22, 2022. Data will be presented during six oral presentations at the conference.
Novavax presentations during CDIC:
|
Toback, S |
Ongoing Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine in the United Kingdom |
Oral (encore) Monday, June 20, 2022 1:30 PM - 3:00 PM AEST |
|
Shinde, V |
Phase 3 trial of a SARS-CoV-2 Protein Vaccine (NVX-CoV2373) in Adolescents (PREVENT-19) |
Oral (encore) Monday, June 20, 2022 1:30 PM - 3:00 PM AEST |
|
Beyhaghi, H |
Reported Pregnancies and Associated Outcomes Across the Novavax COVID-19 Vaccine Clinical Program |
Oral (encore) Monday, June 20, 2022 3:30 PM - 5:00 PM AEST |
|
Marchese, A |
COVID-19 Vaccine Receptivity and Preferences among Vaccine Hesitant Individuals |
Oral (encore) Monday, June 20, 2022 3:30 PM - 5:00 PM AEST |
|
Toback, S |
The Safety and Efficacy of NVX-CoV2373 Co-administered With Seasonal Influenza Vaccine |
Oral (encore) Tuesday, June 21, 2022 1:30 PM - 3:00 PM AEST |
|
Shinde, V |
Long-term polyfunctional CD4+ T-cell responses after recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccination |
Oral (encore) Tuesday, June 21, 2022 1:30 PM - 3:00 PM AEST |